IMMURON LTD-SPON ADR (IMRN) Stock Price & Overview

NASDAQ:IMRNUS45254U1016

Current stock price

0.7 USD
0 (-0.43%)
At close:
0.7 USD
0 (0%)
After Hours:

The current stock price of IMRN is 0.7 USD. Today IMRN is down by -0.43%. In the past month the price decreased by -7.89%. In the past year, price decreased by -62.16%.

IMRN Key Statistics

52-Week Range0.6765 - 2.39
Current IMRN stock price positioned within its 52-week range.
1-Month Range0.7 - 0.8943
Current IMRN stock price positioned within its 1-month range.
Market Cap
5.658M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.45
Dividend Yield
N/A

IMRN Stock Performance

Today
-0.43%
1 Week
-11.53%
1 Month
-7.89%
3 Months
-20.90%
Longer-term
6 Months -63.82%
1 Year -62.16%
2 Years -73.38%
3 Years -62.67%
5 Years -89.01%
10 Years N/A

IMRN Stock Chart

IMMURON LTD-SPON ADR / IMRN Daily stock chart

IMRN Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to IMRN. When comparing the yearly performance of all stocks, IMRN is a bad performer in the overall market: 93.03% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

IMRN Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to IMRN. While IMRN seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IMRN Earnings

Next Earnings DateN/A
Last Earnings DateFeb 26, 2026
PeriodQ2 / 2026
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

IMRN Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

IMRN Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

IMRN Financial Highlights

Over the last trailing twelve months IMRN reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS increased by 41.93% compared to the year before.


Income Statements
Revenue(TTM)7.48M
Net Income(TTM)-4.65M
Industry RankSector Rank
PM (TTM) N/A
ROA -30.69%
ROE -35.53%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%35.78%
Sales Q2Q%4.76%
EPS 1Y (TTM)41.93%
Revenue 1Y (TTM)14.3%

IMRN Ownership

Ownership
Inst OwnersN/A
Shares8.08M
Float6.94M
Ins Owners7.03%
Short Float %0.39%
Short Ratio0.58

About IMRN

Company Profile

IMRN logo image Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.

Company Info

IPO: 1999-04-30

IMMURON LTD-SPON ADR

62 Lygon Street, Level 3

Melbourne VICTORIA 3053 AU

CEO: Jerry Kanellos

Employees: 7

IMRN Company Website

IMRN Investor Relations

Phone: 61398245254

IMMURON LTD-SPON ADR / IMRN FAQ

What does IMRN do?

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.


What is the current price of IMRN stock?

The current stock price of IMRN is 0.7 USD. The price decreased by -0.43% in the last trading session.


What is the dividend status of IMMURON LTD-SPON ADR?

IMRN does not pay a dividend.


How is the ChartMill rating for IMMURON LTD-SPON ADR?

IMRN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is IMMURON LTD-SPON ADR worth?

IMMURON LTD-SPON ADR (IMRN) has a market capitalization of 5.66M USD. This makes IMRN a Nano Cap stock.